Antibody (Suitable for clinical applications)
Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
|Recommended Dilution (Conc)||1:25-1:50|
|Pretreatment||Citrate Buffer pH 6.0|
|Incubation Parameters||30 min at Room Temperature|
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Anti-Cytokeratin 17 Antibody Clone: E3
Host and Isotype: Mouse IgG2b, kappa
Recommended Positive Control Sample: Skin
Cellular Localization of Antibody E3 Staining: Cytoplasmic
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: Cytoskeletal fraction of rat colon epithelium.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.
Cytokeratin 17 Information for Pathologists
Summary:Molecular weight of 48 kDa. Basal type cytokeratin (also 34betaE12, CK5/6, CK14) of complex epithelia but not in stratified or simple epithelia (Eur J Cell Biol 1992;59:127). Rapidly induced in wounded stratified epithelia (also CK 6, CK16); regulates cell growth through binding to the adaptor protein 14-3-3sigma (Nature 2006;441:362). Mutations cause pachyonychia congenita type 2 (J Dermatol 2006;33:161) or steatocystoma multiplex (Br J Dermatol 1998;139:475). Uses by pathologists
Common Uses By Pathologists:Distinguish pancreatobiliary adenocarcinoma (CK17+) from extra-pancreatobiliary nonmucinous adenocarcinoma (CK17-, Am J Surg Pathol 2005;29:359). Distinguish cholangiocarcinoma (60% are CK17+) from hepatocellular carcinoma (CK17-, J Gastrointestin Liver Dis 2006;15:9). Distinguish renal urothelial carcinoma (CK5/CK6+, CK17+, vimentin-) from collecting duct carcinoma (CK5/CK6-, CK17-, vimentin+, Am J Surg Pathol 2005;29:747). Considered a marker of or associated with the basal phenotype (also CK 5/6, CK 14) of invasive or in situ ductal carcinoma of breast (Mod Pathol 2006;19:1506). Sensitive marker of sentinel nodal metastases by RT-PCR in oral squamous cell carcinoma (Clin Cancer Res 2006;12:2498).
Limitations and Warranty
This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.
There are no reviews yet.